BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer

Reuters11-14

Nov 14 (Reuters) - Nuvectis Pharma Inc :

* NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER

* NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA EXPECTED IN Q2 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483871621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483871621","market":"us","top_or_hot":-1,"title":"BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer","media":"Reuters","content":"<html><body><p>Nov 14 (Reuters) - Nuvectis Pharma Inc   :</p><p>   * NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER</p><p>   * NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA EXPECTED IN Q2 2025</p><p>Source text:   Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 14 (Reuters) - Nuvectis Pharma Inc   :   * NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483871621","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483871621","pubTimestamp":1731587103,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 14  - Nuvectis Pharma Inc   :   * NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER   * NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA EXPECTED IN Q2 2025Source text:   Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NVCT":"Nuvectis Pharma, Inc."},"translate_title":"简介-Nuvectis Pharma报告令人鼓舞的NXP800中期数据支持正在进行的铂耐药Arid1a突变卵巢癌患者1B期研究的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1},"content_text":"Nov 14 (Reuters) - Nuvectis Pharma Inc   :   * NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER   * NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA EXPECTED IN Q2 2025Source text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483871621"}